GRIK1 genotype moderates topiramate's effects on daily drinking level, expectations of alcohol's positive effects and desire to drink

International Journal of Neuropsychopharmacology

Volumn 17, Issue 10, 2014, Pages 1549-1556

  Kranzler, Henry R ^a   Armeli, Stephen ^b   Feinn, Richard ^c   Tennen, Howard ^d   Gelernter, Joel ^e,f   Covault, Jonathan ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b FAIRLEIGH DICKINSON UNIVERSITY   (United States)

^c New York   (United States)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

GRIK1; Heavy drinking; Pharmacogenetics; Subjective effects; Topiramate

Indexed keywords

FRUCTOSE; GLUK1 KAINATE RECEPTOR; KAINIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; TOPIRAMATE;

ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFECTS; DRUG THERAPY; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; PHARMACOGENETICS; PHYSIOLOGY; PROSPECTIVE STUDY; PSYCHOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; ALCOHOL DRINKING; DOUBLE-BLIND METHOD; DRINKING BEHAVIOR; FEMALE; FRUCTOSE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PATIENT COMPLIANCE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; QUESTIONNAIRES; RECEPTORS, KAINIC ACID; TREATMENT OUTCOME;

EID: 84925804934     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145714000510     Document Type: Article

References (37)

1. Anton RF, Moak DH, Latham P (1995) The obsessive compulsive drinking scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior. Alcohol Clin Exp Res 19:92-99.
2. Bäckström P, Hyytiä P (2004) Ionotropic glutamate receptor antagonists modulate cue-induced reinstatement of ethanol-seeking behavior. Alcohol Clin Exp Res 28:558-565.
3. Bohn MJ, Krahn DD, Staehler BA (1995) Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19:600-606.
4. Dagne G, Brown C, Howe G (2007) Hierarchical modeling of sequential behavior data: Examining complex association patterns in mediation models. Psychol Methods 12:298-316.
5. Fromme K, Stroot EA, Kaplan D (1993) Comprehensive effects of alcohol: Development and psychometric assessment of a new expectancy questionnaire. Psychol Assessment 5:19-26.
6. Gibbs JW 3rd, Sombati S, DeLorenzo RJ, Coulter DA (2000) Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 41:S10-S16.
7. Grotmol KS, Vaglum P, Ekeberg Ø, Gude T, Aasland OG, Tyssen R (2010) Alcohol expectancy and hazardous drinking: a 6-year longitudinal and nationwide study of medical doctors. Eur Addict Res 16:17-22.
8. Gryder DS, Rogawski MA (2003) Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 23:7069-7074.
9. Halder I, Yang BZ, Kranzler HR, Stein MB, Shriver MD, Gelernter J (2009) Measurement of admixture proportions and description of admixture structure in different U.S. populations. Hum Mutat 30:1299-1309.
10. Hasking P, Lyvers M, Carlopio C (2011) The relationship between coping strategies, alcohol expectancies, drinking motives and drinking behaviour. Addict Behav 36:479-487.
11. Holmes A, Spanagel R, Krystal JH (2013) Glutamatergic targets for new alcohol medications. Psychopharmacology 229:539-554.
12. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677-1685.
13. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641-1651.
14. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Addolorato G, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM; for the Topiramate for Alcoholism Advisory Board and the Topiramate for Alcoholism Study Group (2008) Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med 168:1188-1199.
15. Jones BT, Corbin W, Fromme K (2001) A review of expectancy theory and alcohol consumption. Addiction 96:57-72.
16. Kaminski RM, Banerjee M, Rogawski MA (2004) Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 46:1097-1104.
17. Keller MC (2014) Gene x environment interaction studies have not properly controlled for potential confounders: the problem and the (simple) solution. Biol Psychiatry 75:18-24.
18. Kranzler HR, Abu-Hasaballah K, Tennen H, Feinn R, Young K (2004) Using daily interactive voice response technology to measure drinking and related behaviors in a pharmacotherapy study. Alcohol Clin Exp Res 28:1060-1064.
19. Kranzler HR, Gelernter J, Anton RF, Arias AJ, Herman A, Zhao H, Burian L, Covault J (2009) Association of markers in the 3′ region of the GluR5 kainate receptor subunit gene to alcohol dependence. Alcohol Clin Exp Res 33:925-930.
20. Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, Gelernter J, Pond T, Oncken C, Kampman KM (2014) Topiramate treatment of heavy drinkers: Moderation by a GRIK1 polymorphism. Am J Psychiatry 171:445-52.
21. Leigh BC, Stacy AW (1993) Alcohol outcome expectancies: Scale construction and predictive utility in higher order confirmatory models. Psychol Assessment 5:216-229.
22. Likhitsathian S, Uttawichai K, Booncharoen H, Wittayanookulluk A, Angkurawaranon C, Srisurapanont M (2013) Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial. Drug Alcohol Depend 133:440-446.
23. McDonald R, Rogawski M (2006) Cellular effects of antiepileptic drugs, in Epilepsy: a comprehensive textbook, Second Edition. Philadelphia: Lippincott, Williams, & Wilkins.
24. Miranda R Jr., MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J (2008) Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32:489-497.
25. Nicolai J, Moshagen M, Demmel R (2012) Patterns of alcohol expectancies and alcohol use across age and gender. Drug Alcohol Depend 126:347-343.
26. Pettinati H, Weiss R, Miller W, Donovan D, Ernst D, Rounsaville B (2004) COMBINE Monograph series, Volume 2. Medical management treatment manual: a clinical research guide for medically trained clinicians providing pharmacotherapy as part of the treatment for alcohol dependence (DHHS Publication No. NIH 04-5289). Bethesda: NIAAA.
27. Preacher KJ, Zyphur MJ, Zhang Z (2010) A general multilevel SEM framework for assessing multilevel mediation. Psychol Methods 15:209-233.
28. Rohsenow DJ (1983) Drinking habits and expectancies about alcohol's effects for self vs. others. J Consult Clin Psych 51:752-756.
29. Sanchez-Craig M, Wilkinson DA, Davila R (1995) Empirically based guidelines for moderate drinking: 1-year results from three studies with problem drinkers. Am J Public Health 85:823-828.
30. Sawayama T, Yoneda J, Tanaka K, Shirakawa N, Sawayama E, Ikeda T, Higuchi S, Miyaoka H (2012) The predictive validity of the Drinking-Related Cognitions Scale in alcohol-dependent patients under abstinence-oriented treatment. Subst Abuse Treat Prev Policy 7:17.
31. Skradski S, White HS (2000) Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 41:S45-S47.
32. Sommer BR, Mitchell EL, Wroolie TE (2013) Topiramate: Effects on cognition in patients with epilepsy, migraine headache and obesity. Ther Adv Neurol Disord 6:211-227.
33. Tabakoff B, Hoffman PL (2013) The neurobiology of alcohol consumption and alcoholism: an integrative history. Pharmacol Biochem Behav 113:20-37.
34. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, Kang HM, Marth GT, McVean GA (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491:56-65.
35. Werner MJ, Walker LS, Greene JW (1995) Relation of alcohol expectancies to changes in problem drinking among college students. Arch Pediat Adol Med 149:733-739.
36. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH (2000) Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 41:S17-S20.
37. Zamboanga BL, Horton NJ, Leitkowski LK, Wang SC (2006) Do good things come to those who drink? A longitudinal investigation of drinking expectancies and hazardous alcohol use in female college athletes. J Adolescent Health 39:229-236.